UNIGE document Scientific Article
previous document  unige:748  next document
add to browser collection

Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva)

Masouyé, Isabelle
Published in Dermatology. 2008, vol. 216, no. 3, p. 247-9
Abstract Erlotinib is a small molecule tyrosine kinase inhibitor that is used as an anticancer agent. Most patients develop a pustular facial dermatitis within the first week of treatment. Pyogenic granulomas of the nail folds are another typical adverse event occurring in about 10-15% of cases. We report on a patient who developed a generalized dermatitis characterized by neutrophilic spongiosis. Neutrophilic inflammation has been observed in several drugs that interfere with EGFR signaling, suggesting a class effect. The present case may be yet another manifestation of this particular reaction pattern.
Keywords Antineoplastic Agents/adverse effectsCarcinoma Renal Cell/drug therapy/secondaryDermatitis/etiology/pathologyDrug Eruptions/etiology/pathologyFemaleHumansKidney Neoplasms/drug therapy/pathologyMiddle AgedNeutrophilsProtein Kinase Inhibitors/adverse effectsQuinazolines/adverse effectsReceptor Epidermal Growth Factor/antagonists & inhibitorsSkin/pathology
PMID: 18182820
Full text
Research group Immunothérapie des cancers (42)
(ISO format)
LUBBE, Jann, MASOUYÉ, Isabelle, DIETRICH, Pierre-Yves. Generalized xerotic dermatitis with neutrophilic spongiosis induced by erlotinib (Tarceva). In: Dermatology, 2008, vol. 216, n° 3, p. 247-9. doi: 10.1159/000112936 https://archive-ouverte.unige.ch/unige:748

333 hits

1 download


Deposited on : 2009-02-11

Export document
Format :
Citation style :